Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer

被引:25
|
作者
Hurria, A [1 ]
Hurria, A [1 ]
Brogan, K [1 ]
Panageas, KS [1 ]
Pearce, C [1 ]
Norton, L [1 ]
Jakubowski, A [1 ]
Howard, J [1 ]
Hudis, C [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
D O I
10.2165/00002512-200522090-00007
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective: A number of age-related physiological changes contribute to an increased risk of toxicity of cancer chemotherapy in the elderly. One of the most important of these changes is the progressive decline in renal function with aging. We sought to determine the association between calculated creatinine clearance (CLCR) and grade 3 or 4 toxicities during adjuvant chemotherapy in women >= 65 years of age with breast cancer. Design and methods: We identified 1405 patients >= 65 years of age who had been treated for primary invasive breast cancer at Memorial Sloan-Kettering Cancer Center between January 1998 and December 2000. Patients were included in this analysis if they had stage I-III breast cancer and had received adjuvant chemotherapy. Patients were excluded if they had a prior history of breast cancer or chemotherapy, or had no baseline creatinine value available for review. Results: The 126 patients who met our criteria had received either cyclophosphamide, methotrexate and fluorouracil (CMF) [n = 65, mean age 7 1, range 65-78] or an anthracycline-based regimen (n = 61, mean age 69, range 65-79). The majority of patients (97%) had a normal creatinine. CLCR, as calculated by the Cockcroft-Gault and Jeliffe formulas, decreased with increasing age (increased age associated with decreased Cockcroft-Gault [p = 0.02]; increased age associated with decreased Jeliffe [p < 0.01]). In multivariate analysis, after controlling for age and co-morbidity, a CLCR <50 mL/min by the Cockcroft-Gault formula was associated with an increased risk of fever and neutropenia (odds ratio [OR] 3.60; 95% CI 1.00, 12.94; p = 0.05) and a CLCR <50 mL/min by the Jeliffe formula was associated with a trend towards an increased risk of fever and neutropenia (OR 3.30; 95% CI 0.91, 12.33; p = 0.07), grade 3 or 4 haematological toxicity (OR 2.43; 95% CI 0.90, 6.55; p = 0.08), and need for erythropoietin (OR 4.15; 95% CI 0.81, 2.99; p = 0.09). An increase in creatinine (as a continuous variable) was associated with a trend towards an increased risk of grade 3 or 4 haematological toxicity (OR 5.81; 95% CI 0.96, 35.33; p = 0.06). Conclusions: In this cohort of older breast cancer patients, a decreased CLCR and increased creatinine was associated with an increased risk of fever and neutropenia or haematological toxicity. CLCR should be considered when determining chemotherapy dosage in the elderly.
引用
收藏
页码:785 / 791
页数:7
相关论文
共 50 条
  • [31] Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy
    Mayerhofer, Christina
    Sedrak, Mina S.
    Hopkins, Judith O.
    Li, Tianyu
    Tayob, Nabihah
    Faggen, Meredith G.
    Sinclair, Natalie F.
    Chen, Wendy Y.
    Parsons, Heather A.
    Mayer, Erica L.
    Lange, Paulina B.
    Basta, Ameer S.
    Perilla-Glen, Adriana
    Lederman, Ruth, I
    Wong, Andrew R.
    Tiwari, Abhay
    McAllister, Sandra S.
    Mittendorf, Elizabeth A.
    Gibson, Christopher J.
    Burstein, Harold J.
    Kim, Annette S.
    Freedman, Rachel A.
    Miller, Peter G.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (08): : 981 - 988
  • [32] Prognostic significance of GRP78 expression patterns in breast cancer patients receiving adjuvant chemotherapy
    Baptista, Mauricio Z.
    Sarian, Luis Otavio
    Vassallo, Jose
    Pinto, Glauce A.
    Soares, Fernando A.
    de Souza, Gustavo Antonio
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2011, 26 (03): : 188 - 196
  • [33] Predictors of Toxicity and Toxicity Profile of Adjuvant Chemotherapy in Elderly Breast Cancer Patients
    Garg, Praveen
    Rana, Fauzia
    Gupta, Ruchi
    Buzaianu, Elena M.
    Guthrie, Troy H.
    BREAST JOURNAL, 2009, 15 (04): : 404 - 408
  • [34] Fatigue in patients with breast cancer receiving adjuvant chemotherapy: A review of the literature
    de Jong, N
    Courtens, AM
    Abu-Saad, HH
    Schouten, HC
    CANCER NURSING, 2002, 25 (04) : 283 - 297
  • [35] Fatigue in early breast cancer patients receiving adjuvant postoperative chemotherapy
    Heras, P.
    Hatzopoulos, A.
    Kritikos, K.
    Kapouralos, A.
    Androutsos, N.
    BREAST, 2009, 18 : S70 - S70
  • [36] BRAIN METASTASES IN BREAST-CANCER PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY
    PATERSON, AHG
    AGARWAL, M
    LEES, A
    HANSON, J
    SZAFRAN, O
    CANCER, 1982, 49 (04) : 651 - 654
  • [37] The development of anticipatory nausea in patients receiving adjuvant chemotherapy for breast cancer
    Montgomery, GH
    Bovbjerg, DH
    PHYSIOLOGY & BEHAVIOR, 1997, 61 (05) : 737 - 741
  • [38] QUALITY OF LIFE FOR BREAST-CANCER PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY
    MEYEROWITZ, BE
    WATKINS, IK
    SPARKS, FC
    AMERICAN JOURNAL OF NURSING, 1983, 83 (02) : 232 - 235
  • [39] Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy
    de Jong, N
    Candel, MJJM
    Schouten, HC
    Abu-Saad, HH
    Courtens, AM
    ANNALS OF ONCOLOGY, 2004, 15 (06) : 896 - 905
  • [40] Energy Balance in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy
    Michelle N. Harvie
    I.T. Campbell
    A. Baildam
    A. Howell
    Breast Cancer Research and Treatment, 2004, 83 : 201 - 210